Retrospective Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Dec 15, 2020; 12(12): 1416-1427
Published online Dec 15, 2020. doi: 10.4251/wjgo.v12.i12.1416
Clinicopathological characteristics and prognosis of 77 cases with type 3 gastric neuroendocrine tumours
Yuan-Liang Li, Xu-Dong Qiu, Jie Chen, Yu Zhang, Jie Li, Jian-Ming Xu, Chao Wang, Zhi-Rong Qi, Jie Luo, Huang-Ying Tan
Yuan-Liang Li, Xu-Dong Qiu, Beijing University of Chinese Medicine, Beijing 100029, China
Yuan-Liang Li, Xu-Dong Qiu, Chao Wang, Zhi-Rong Qi, Huang-Ying Tan, Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing 100029, China
Jie Chen, Yu Zhang, Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, Guangdong Province, China
Jie Li, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Beijing Cancer Hospital, Beijing 100037, China
Jian-Ming Xu, Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing 100071, China
Jie Luo, Department of Pathology, China-Japan Friendship Hospital, Beijing 100029, China
Author contributions: Li YL and Qiu XD contributed equally to this work and should be considered as co-first authors; Li YL and Qiu XD wrote the paper; Li YL and Tan HY designed the research; Qiu XD, Chen J, Zhang Y, Li J, and Xu JM collected the data; Wang C and Qi ZR analysed the data; Luo J reviewed the pathology; Tan HY revised the paper.
Supported by National Natural Science Foundation of China, No. 81673763; Foundation of Guangzhou Science and Technology Plan, No. 201804010078.
Institutional review board statement: The study was reviewed and approved by the clinical research ethics committee of the China-Japan Friendship Hospital (No. 2019-24-K18-1).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that no competing interests exist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Noncommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Huang-Ying Tan, MD, PhD, Professor, Department of Integrative Oncology, China-Japan Friendship Hospital, No. 2 Yinghuadong Street, Beijing 100029, China. tanhuangying@263.net
Received: July 11, 2020
Peer-review started: July 11, 2020
First decision: September 17, 2020
Revised: September 28, 2020
Accepted: October 28, 2020
Article in press: October 28, 2020
Published online: December 15, 2020
Core Tip

Core Tip: Type 3 gastric neuroendocrine tumours (g-NETs) were heterogeneous based on the 2019 WHO pathological classification. Endoscopic treatment was safe and effective for patients with G1 NETs having tumours under 2 cm, confined to the mucosa or submucosa. The prognosis of type 3 g-NETs was related to stage and grade, which were its independent prognostic factors, and the 2019 WHO pathological classification was effective to predict the biological behaviors and prognosis of type 3 g-NETs.